Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18422101 | 0.85 | CHRM2 (0.42) | EPHX2MGLL | |
| SCHEMBL10241579 | 0.82 | EPHX2 (0.40) | EPHX2MGLL | |
| Trifluoroacetic Acid SCHEMBL1246075 | 0.81 | EPHX2 (0.38) | EPHX2MGLL | |
| SCHEMBL2142168 | 0.81 | USP2 (0.49) | EPHX2MGLL | |
| SCHEMBL19097004 | 0.76 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL30545528 | 0.75 | CHRM2 (0.39) | EPHX2MGLL | |
| SCHEMBL18341792 | 0.74 | VNN1 (0.37) | EPHX2MGLL | |
| SCHEMBL31548277 | 0.74 | CNR2 (0.37) | EPHX2MGLL | |
| SCHEMBL17318867 | 0.72 | CHRM2 (0.65) | EPHX2MGLL | |
| SCHEMBL30900658 | 0.72 | VNN1 (0.38) | EPHX2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | EPHX2 1056/4885MGLL 4101/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | EPHX2 1481/4885MGLL 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.